difenamizole hydrochloride

Ruboxistaurin mesylate monohydrate is a PKC beta inhibitor potentially for the treatment of diabetic nephropathy and diabetic macular edema. Ruboxistaurin attenuates diabetic nephropathy via modulation of TGF-β1 Smad and GRAP pathways. Ruboxistaurin reduces oxidative stress and attenuates left ventricular hypertrophy and dysfunction in rats with streptozotocin-induced diabetes. Ruboxistaurin inhibits retinal neovascularization via suppression of phosphorylation of ERK1 2 and Akt.

Ruboxistaurin is a PKC beta inhibitor. Ruboxistaurin reduces oxidative stress and attenuates left ventricular hypertrophy and dysfunction in rats with streptozotocin-induced diabetes. Ruboxistaurin attenuates diabetic nephropathy via modulation of TGF-β1/

Ruboxistaurin (LY333531) 是一种选择性的、口服具有活力的 PKC beta 抑制剂，其 Ki 值为 2 nM。Ruboxistaurin 以 ATP 依赖性的方式竞争性抑制 PKC beta I (IC50: 4.7 nM)。Ruboxistaurin 能够作用于 PKC beta II (IC50: 5.9 nM)。

Ruboxistaurin hydrochloride (LY 333531 hydrochloride) 是蛋白激酶 C(PKC) 的同工酶选择性抑制剂，竞争性且可逆地抑制 PKCβI 和 PKCβII，IC50 值分别为 4.7 和 5.9 nM。